ARTICLE | Clinical News
Bydureon: Phase III data
September 26, 2016 7:00 AM UTC
The double-blind, international Phase III DURATION-8 trial in 695 Type II diabetics inadequately controlled on metformin showed that once-weekly 2 mg subcutaneous Bydureon exenatide plus once-daily 10...